Bone Biologics Co. (NASDAQ:BBLG) Short Interest Up 9.8% in December

Bone Biologics Co. (NASDAQ:BBLG) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 55,100 shares, an increase of 9.8% from the December 15th total of 50,200 shares. Currently, 10.3% of the shares of the company are short sold. Based on an average trading volume of 224,100 shares, the short-interest ratio is currently 0.2 days.

Bone Biologics Price Performance

Shares of NASDAQ BBLG traded up $0.02 during trading hours on Friday, reaching $0.98. 26,414 shares of the stock were exchanged, compared to its average volume of 197,204. The stock’s fifty day simple moving average is $1.11 and its 200 day simple moving average is $1.43. Bone Biologics has a 52 week low of $0.80 and a 52 week high of $4.74.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.